Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drug utilisation registry for Teflaro (ceftaroline fosamil)

Trial Profile

Drug utilisation registry for Teflaro (ceftaroline fosamil)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftaroline fosamil (Primary)
  • Indications Bacteraemia; Bacterial endocarditis; Community-acquired pneumonia; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Osteomyelitis; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Acronyms CAPTURE
  • Sponsors Cerexa; Forest Laboratories
  • Most Recent Events

    • 08 Oct 2017 Results (n=476) related to intensive care unit patients with pneumonia were presented at the IDWeek 2017
    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 04 Oct 2017 According to an Allergan media release, data from the study will be presented At IDWeek 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top